Relic Technologies News

Relic Technologies News 2026

Relic Technologies Stock

Relic Technologies Relic Technologies Ltd is a corporate entity registered in India, identified by the ticker symbol 511712.BO and the ISIN code INE452B01013. The company is headquartered in Mumbai, located in the state of Maharashtra, serving as the central hub for its administrative and operational activities. It operates within the broader financial sector, specifically categorized under the industry of financial services. This classification highlights its involvement in activities that facilitate capital flow and financial intermediation within the Indian market. The firm was publicly listed on the stock exchange on January 31, 1995, marking its entry into the public equity markets and establishing its presence as a traded entity for investors. Structurally, Relic Technologies Ltd functions primarily as a holding company. This organizational model implies that the entity’s main purpose is to own and control other companies rather than producing goods or providing services directly to end consumers. By maintaining a holding structure, the company can manage its investments and oversee the strategic direction of its subsidiaries while potentially diversifying its risk profile across different business units. A key component of its corporate structure is its subsidiary, Relic Pharma Limited. The existence of this subsidiary indicates that the holding company has expanded its interests beyond its core operational focus. While Relic Technologies Ltd is engaged in the share broking business, the ownership of a pharmaceutical entity suggests a diversified portfolio approach. Share broking involves acting as an intermediary between buyers and sellers of securities, facilitating transactions on stock exchanges and earning commissions or fees for these services. This activity places the company directly within the competitive landscape of financial intermediaries in India. The combination of its role as a holding company, its engagement in share broking, and its ownership of a pharmaceutical subsidiary creates a unique corporate profile. Investors and analysts examining the company would consider its financial health, regulatory compliance in the financial services sector, and the performance of its subsidiary when evaluating its overall market position. The company’s long-standing presence since its 1995 initial public offering provides a historical context for its operations, although specific details regarding its current revenue streams, management team, or recent strategic acquisitions are not detailed in the available factual records. The focus remains on its structural role as a holding entity with specific interests in financial services and pharmaceuticals, anchored in Mumbai.